Association of MGMT Gene Promoter Methylation with Clinicopathological Parameters in Patients with Wild-type IDH Glioblastoma

Moonsik Kim; Jihwan Yoo; Jong Hee Chang; Se Hoon Kim

doi:10.21873/anticanres.15490

Association of MGMT Gene Promoter Methylation with Clinicopathological Parameters in Patients with Wild-type IDH Glioblastoma

Moonsik Kim, Jihwan Yoo, Jong Hee Chang, Se Hoon Kim

Department of Pathology

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

Background: The methylation status of the O⁶methylguanine-DNA methyltransferase (MGMT) promoter plays a key role in response to temozolomide chemotherapy and disease prognosis in patients with wild-type isocitrate dehydrogenase (IDH) glioblastoma (GBM). Patients and Methods: The MGMT promoter methylation status and its association with clinicopathological parameters were retrospectively analysed in a cohort of 316 patients with GBM with wild-type IDH. Results: MGMT methylation was significantly associated with ATRX chromatin remodeler (ATRX) loss and completion of the standard Stupp protocol. The median durations of overall and progression-free survival for the unmethylated, low-methylated (10-39%), and hypermethylated (≥40%) groups were 15, 23, and 30 months and 11, 18, and 21 months, respectively. However, the improvement in the survival of the hypermethylated group was not statistically significant. Conclusion: We suggest a possible association between MGMT methylation status and ATRX mutations in GBM with wild-type IDH.

Original language	English
Pages (from-to)	335-341
Number of pages	7
Journal	Anticancer research
Volume	42
Issue number	1
DOIs	https://doi.org/10.21873/anticanres.15490
Publication status	Published - 2022 Jan

Bibliographical note

Funding Information:
Se Hoon Kim was supported by grants from the Brain Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Science, ICT & Future Planning (Grant No. 2016M3C7A1913844). The funding source had no role in the design, practice, or analysis of this study.

Publisher Copyright:
© 2022 International Institute of Anticancer Research. All rights reserved.

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.21873/anticanres.15490

Cite this

@article{5bd7190353e744d5b3c7301a37cf0900,

title = "Association of MGMT Gene Promoter Methylation with Clinicopathological Parameters in Patients with Wild-type IDH Glioblastoma",

abstract = "Background: The methylation status of the O6methylguanine-DNA methyltransferase (MGMT) promoter plays a key role in response to temozolomide chemotherapy and disease prognosis in patients with wild-type isocitrate dehydrogenase (IDH) glioblastoma (GBM). Patients and Methods: The MGMT promoter methylation status and its association with clinicopathological parameters were retrospectively analysed in a cohort of 316 patients with GBM with wild-type IDH. Results: MGMT methylation was significantly associated with ATRX chromatin remodeler (ATRX) loss and completion of the standard Stupp protocol. The median durations of overall and progression-free survival for the unmethylated, low-methylated (10-39%), and hypermethylated (≥40%) groups were 15, 23, and 30 months and 11, 18, and 21 months, respectively. However, the improvement in the survival of the hypermethylated group was not statistically significant. Conclusion: We suggest a possible association between MGMT methylation status and ATRX mutations in GBM with wild-type IDH.",

author = "Moonsik Kim and Jihwan Yoo and Chang, {Jong Hee} and Kim, {Se Hoon}",

note = "Funding Information: Se Hoon Kim was supported by grants from the Brain Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Science, ICT & Future Planning (Grant No. 2016M3C7A1913844). The funding source had no role in the design, practice, or analysis of this study. Publisher Copyright: {\textcopyright} 2022 International Institute of Anticancer Research. All rights reserved.",

year = "2022",

month = jan,

doi = "10.21873/anticanres.15490",

language = "English",

volume = "42",

pages = "335--341",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "1",

}

TY - JOUR

T1 - Association of MGMT Gene Promoter Methylation with Clinicopathological Parameters in Patients with Wild-type IDH Glioblastoma

AU - Kim, Moonsik

AU - Yoo, Jihwan

AU - Chang, Jong Hee

AU - Kim, Se Hoon

N1 - Funding Information: Se Hoon Kim was supported by grants from the Brain Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Science, ICT & Future Planning (Grant No. 2016M3C7A1913844). The funding source had no role in the design, practice, or analysis of this study. Publisher Copyright: © 2022 International Institute of Anticancer Research. All rights reserved.

PY - 2022/1

Y1 - 2022/1

N2 - Background: The methylation status of the O6methylguanine-DNA methyltransferase (MGMT) promoter plays a key role in response to temozolomide chemotherapy and disease prognosis in patients with wild-type isocitrate dehydrogenase (IDH) glioblastoma (GBM). Patients and Methods: The MGMT promoter methylation status and its association with clinicopathological parameters were retrospectively analysed in a cohort of 316 patients with GBM with wild-type IDH. Results: MGMT methylation was significantly associated with ATRX chromatin remodeler (ATRX) loss and completion of the standard Stupp protocol. The median durations of overall and progression-free survival for the unmethylated, low-methylated (10-39%), and hypermethylated (≥40%) groups were 15, 23, and 30 months and 11, 18, and 21 months, respectively. However, the improvement in the survival of the hypermethylated group was not statistically significant. Conclusion: We suggest a possible association between MGMT methylation status and ATRX mutations in GBM with wild-type IDH.

AB - Background: The methylation status of the O6methylguanine-DNA methyltransferase (MGMT) promoter plays a key role in response to temozolomide chemotherapy and disease prognosis in patients with wild-type isocitrate dehydrogenase (IDH) glioblastoma (GBM). Patients and Methods: The MGMT promoter methylation status and its association with clinicopathological parameters were retrospectively analysed in a cohort of 316 patients with GBM with wild-type IDH. Results: MGMT methylation was significantly associated with ATRX chromatin remodeler (ATRX) loss and completion of the standard Stupp protocol. The median durations of overall and progression-free survival for the unmethylated, low-methylated (10-39%), and hypermethylated (≥40%) groups were 15, 23, and 30 months and 11, 18, and 21 months, respectively. However, the improvement in the survival of the hypermethylated group was not statistically significant. Conclusion: We suggest a possible association between MGMT methylation status and ATRX mutations in GBM with wild-type IDH.

UR - http://www.scopus.com/inward/record.url?scp=85121986729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85121986729&partnerID=8YFLogxK

U2 - 10.21873/anticanres.15490

DO - 10.21873/anticanres.15490

M3 - Article

C2 - 34969742

AN - SCOPUS:85121986729

VL - 42

SP - 335

EP - 341

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 1

ER -

Association of MGMT Gene Promoter Methylation with Clinicopathological Parameters in Patients with Wild-type IDH Glioblastoma

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this